Mozambique ANARME: Achieves WHO ML3 for Medicine Regulation

• Mozambique's National Medicine Regulatory Authority (ANARME) has achieved Maturity Level 3 (ML3) from the World Health Organization (WHO) for regulating medicines and imported vaccines.
• This designation confirms ANARME operates a stable, well-functioning, and integrated regulatory system, making Mozambique the 10th African country and first Portuguese-speaking nation to reach ML3.
• The achievement follows years of sustained efforts and close collaboration with WHO, utilizing its Global Benchmarking Tool (GBT) to assess and strengthen regulatory functions.
• Stronger regulation ensures greater assurance of product quality, safety, and efficacy, enhancing the country's ability to combat substandard products and improve public health outcomes.
• Mozambique's ML3 status strengthens the African regulatory ecosystem and provides a foundation for the African Medicines Agency (AMA) to advance regional convergence and cooperation.

A stronger regulatory framework, as confirmed by ML3, provides greater assurance that medicines and vaccines undergo appropriate evaluation for quality, safety, and efficacy, and are continuously monitored throughout their lifecycle.

Mozambique's National Medicine Regulatory Authority (ANARME) has achieved a significant milestone, being classified at Maturity Level 3 (ML3) by the World Health Organization (WHO) for its robust oversight of medicines and imported vaccines. This designation, part of the WHO's global classification system for national regulatory authorities, signifies that ANARME operates a stable, well-functioning, and integrated regulatory system. This achievement places Mozambique among a select group of ten African nations to reach ML3, joining countries such as Egypt, Ethiopia, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania, and Zimbabwe, and underscores a growing momentum in strengthening regulatory frameworks across the continent. Notably, Mozambique is the first Portuguese-speaking country in Africa to attain this level, highlighting its unique contribution to regional regulatory development. The WHO's maturity levels range from 1 to 4, with ML3 confirming a system capable of ensuring the quality, safety, and efficacy of health products.

The attainment of ML3 by ANARME is the culmination of years of dedicated effort to build essential institutions and capabilities for effective regulation. The World Health Organization played a crucial role in this process, working closely with ANARME to assess its national regulatory system using the comprehensive Global Benchmarking Tool (GBT). This tool evaluates a broad spectrum of regulatory functions vital for ensuring the quality, safety, and efficacy of medical products. These functions include the rigorous processes of registration and marketing authorization, licensing, ongoing market surveillance and control, pharmacovigilance, regulatory inspection, laboratory testing, and the oversight of clinical trials where applicable. A stronger regulatory framework, as confirmed by ML3, provides greater assurance that medicines and vaccines undergo appropriate evaluation for quality, safety, and efficacy, and are continuously monitored throughout their lifecycle. This enhanced oversight also significantly bolsters Mozambique's capacity to detect and respond to safety concerns, as well as to combat substandard or falsified products, thereby supporting timely access to quality-assured health products and reinforcing Mozambique pharmaceutical compliance. While ML3 signifies a stable and integrated system, ML4 represents an even more advanced framework focused on continuous improvement.

This significant achievement by Mozambique's ANARME is expected to yield substantial benefits for public health, as articulated by Dr. Sylvie Briand, Director of the Epidemic and Pandemic Preparedness and Prevention department (EPP) at WHO. Dr. Briand emphasized that this progress stems from sustained investment in regulatory capacity, which is vital for protecting populations, fostering confidence in health products, and enabling countries to effectively address evolving public health needs and challenges. Beyond its national impact, Mozambique's advancement contributes directly to strengthening regulatory capacity across the African continent and promoting more equitable access to safe and quality-assured medicines and vaccines. As the first Portuguese-speaking nation in Africa to reach ML3, Mozambique's experience offers a unique opportunity to foster greater cooperation, knowledge sharing, and reliance among Portuguese-speaking countries, as well as across the broader African region. This development further solidifies a more interconnected African regulatory ecosystem, providing a crucial foundation for the newly established African Medicines Agency (AMA) to build upon. The African Medicines Agency Mozambique impact is thus enhanced, facilitating its mission to advance regulatory convergence and cooperation throughout the region.

Legal and compliance teams in the pharmaceutical and healthcare sectors operating in or considering Mozambique should be aware of the significantly strengthened regulatory framework for medicines and vaccines. This indicates a more robust and predictable environment for product approvals, market surveillance, and compliance with quality and safety standards, potentially impacting operational strategies and due diligence.

Source: Original reporting via AIM